Compare · ANGO vs DXCM
ANGO vs DXCM
Side-by-side comparison of AngioDynamics Inc. (ANGO) and DexCom Inc. (DXCM): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ANGO and DXCM operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- DXCM is the larger of the two at $33.65B, about 51.0x ANGO ($659.3M).
- Over the past year, ANGO is up 62.8% and DXCM is up 17.1% - ANGO leads by 45.7 points.
- DXCM has hit the wire 9 times in the past 4 weeks while ANGO has been quiet.
- DXCM has more recent analyst coverage (25 ratings vs 8 for ANGO).
- Company
- AngioDynamics Inc.
- DexCom Inc.
- Price
- $15.95+1.40%
- $89.16-2.09%
- Market cap
- $659.3M
- $33.65B
- 1M return
- +16.94%
- +21.53%
- 1Y return
- +62.76%
- +17.08%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2004
- 2005
- News (4w)
- 0
- 9
- Recent ratings
- 8
- 25
AngioDynamics Inc.
AngioDynamics, Inc. designs, manufactures, and sells various medical, surgical, and diagnostic devices used by professional healthcare providers for the treatment of peripheral vascular disease and vascular access; and for use in oncology and surgical settings in the United States and internationally. The company provides NanoKnife ablation systems for the surgical ablation of soft tissues; solero microwave tissue ablation systems; and radiofrequency ablation products for ablating solid cancerous or benign tumors. It also offers BioSentry tract sealant systems, IsoLoc Endorectal Balloon's, alatus vaginal balloon packing systems, angiographic catheters, guidewires, percutaneous drainage catheters, and coaxial micro-introducer kits. In addition, the company provides vascular interventions and therapies products in the areas of thrombus management, atherectomy, peripheral products (Core), and venous insufficiency. Additionally, the company offers peripherally inserted central catheters, midline catheters, implantable ports, dialysis catheters, and related accessories and supplies that are used primarily to deliver short-term drug therapies, such as chemotherapeutic agents and antibiotics, into the central venous system under the BioFlo, BioFlo Midline, BioFlo PICC, Xcela PICC, PASV, BioFlo Port, SmartPort, Vortex, LifeGuard, BioFlo DuraMax, and DuraMax names. It sells and markets its products to interventional radiologists, interventional cardiologists, vascular surgeons, urologists, interventional and surgical oncologists, and critical care nurses directly, as well as through distributor relationships. The company was founded in 1988 and is headquartered in Latham, New York.
DexCom Inc.
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom G7, a next generation G7 CGM system; and Dexcom Share, a remote monitoring system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop next-generation CGM products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and is headquartered in San Diego, California.
Latest ANGO
- SVP Quality and Regulatory Nighan Warren Jr sold $344,006 worth of shares (23,370 units at $14.72), decreasing direct ownership by 27% to 64,745 units (SEC Form 4)
- AngioDynamics to Participate in Upcoming Investor Conferences
- SVP International Piccinini Laura converted options into 8,047 shares and covered exercise/tax liability with 4,506 shares, increasing direct ownership by 5% to 81,929 units (SEC Form 4) (tax withholding)
- EVP and CFO Trowbridge Stephen A converted options into 16,296 shares and covered exercise/tax liability with 8,319 shares, increasing direct ownership by 3% to 305,796 units (SEC Form 4) (tax withholding)
- President and CEO Clemmer James C converted options into 52,358 shares and covered exercise/tax liability with 26,728 shares, increasing direct ownership by 3% to 862,448 units (SEC Form 4) (for withholding tax)
- SVP Quality and Regulatory Nighan Warren Jr converted options into 5,694 shares and covered exercise/tax liability with 1,671 shares, increasing direct ownership by 5% to 88,115 units (SEC Form 4) to satisfy withholding obligation
- SVP/GM, Vascular Access Campbell Chad Thomas converted options into 6,466 shares and covered exercise/tax liability with 2,330 shares, increasing direct ownership by 4% to 108,676 units (SEC Form 4) to satisfy withholding obligation
- Director Johnson Wesley was granted 11,887 shares, increasing direct ownership by 8% to 155,425 units (SEC Form 4)
- SVP Quality and Regulatory Nighan Warren Jr was granted 17,966 shares, increasing direct ownership by 27% to 84,092 units (SEC Form 4)
- Director Burgess Lorinda was granted 11,887 shares, increasing direct ownership by 22% to 67,144 units (SEC Form 4)
Latest DXCM
- EVP Chief Legal Compliance Off Brown Michael Jon covered exercise/tax liability with 1,451 shares, decreasing direct ownership by 1% to 101,502 units (SEC Form 4) (withholding obligation)
- EVP, Chief Financal Officer Sylvain Jereme M covered exercise/tax liability with 1,451 shares, decreasing direct ownership by 0.96% to 150,390 units (SEC Form 4) (withholding tax)
- President, CEO, and Director Leach Jacob Steven covered exercise/tax liability with 1,451 shares, decreasing direct ownership by 0.35% to 418,908 units (SEC Form 4) to satisfy withholding tax
- EVP Chief People & Culture Off Stern Sadie covered exercise/tax liability with 1,451 shares, decreasing direct ownership by 1% to 128,608 units (SEC Form 4) (withholding tax)
- Executive Chair Sayer Kevin R sold $2,408,242 worth of shares (26,756 units at $90.01) as part of a pre-agreed trading plan, decreasing direct ownership by 8% to 302,214 units (SEC Form 4)
- EVP Chief Legal Compliance Off Brown Michael Jon sold $156,281 worth of shares (1,700 units at $91.93) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 102,953 units (SEC Form 4)
- Director Augustinos Nicholas gifted 1,075 shares (SEC Form 4)
- Director Heller Bridgette P sold $89,349 worth of shares (1,012 units at $88.29) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 29,570 units (SEC Form 4)
- Director Foletta Mark G sold $330,640 worth of shares (4,000 units at $82.66) as part of a pre-agreed trading plan (SEC Form 4)
- SEC Form 10-Q filed by DexCom Inc.